There are over 15 disease-modifying drugs that have been approved over the last 20 years
for the treatment of relapsing–remitting multiple sclerosis (MS), but there are limited …

Importance Although highly effective disease-modifying therapies for multiple sclerosis (MS)
have been associated with an increased risk of infections vs injectable therapies interferon …

The factor that is most relevant and strongly associated with the clinical course of multiple
sclerosis is chronological age. Very young patients exclusively have relapsing remitting …

The success of clinical trials of selective B‐cell depletion in patients with relapsing multiple
sclerosis (MS) and primary progressive MS has led to a conceptual shift in the …

Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous
system (CNS) where immunopathology is thought to be mediated by myelin-reactive CD4+ T …

Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system that
causes significant disability and healthcare burden. The treatment of MS has evolved over …

Multiple sclerosis is an inflammatory demyelinating disease in which active demyelination
and neurodegeneration are associated with lymphocyte infiltrates in the brain. However, so …

The modern era of multiple sclerosis (MS) treatment began 25 years ago, with the approval
of IFNβ and glatiramer acetate for the treatment of relapsing–remitting MS. Ten years later …

Multiple sclerosis (MS) is an immune-mediated disease of the central nervous system that
causes demyelination, axonal degeneration and astrogliosis, resulting in progressive …

B cells are essential components of the adaptive immune system and have important roles
in the pathogenesis of several central nervous system (CNS) diseases. Besides producing …